SOBI and Pharming extend and amend Ruconest agreement

13 October 2014

Biotech companies Pharming Group (Euronext: PHARM) and Swedish Orphan Biovitrum (STO: SOBI) have amended and extended the Ruconest (C1 esterase inhibitor) distribution agreement between the two firms.

Pharming is now to focus on direct commercialization in Austria, Germany and the Netherlands, while SOBI will extend its Ruconest sales territory by adding Azerbaijan, Belarus, Georgia, Kazakhstan, Russia, Serbia and Ukraine.

It has recently started hiring a small team of hereditary angioedema commercialization and medical affairs specialists to take over the direct commercialization activities from SOBI for Ruconest in Austria, Germany and the Netherlands. SOBI will continue to deliver Ruconest as before and will continue the drug safety monitoring and reporting during the remaining months of 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK